---
title: "JW THERAP-B: The clinical phase I study of Regiokalon for the treatment of moderate to severe active SLE shows good safety and significant efficacy"
description: "JW THERAP-B announced that it has submitted Phase I study data of Regiokalonase in adult patients with active systemic lupus erythematosus to the National Medical Products Administration of China. The"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262005727.md"
published_at: "2025-10-21T08:35:10.000Z"
---

# JW THERAP-B: The clinical phase I study of Regiokalon for the treatment of moderate to severe active SLE shows good safety and significant efficacy

> JW THERAP-B announced that it has submitted Phase I study data of Regiokalonase in adult patients with active systemic lupus erythematosus to the National Medical Products Administration of China. The study has enrolled 12 female patients, showing good safety and significant efficacy. Preliminary results indicate that all patients achieved the SRI-4 standard within 6 months, with an LLDAS attainment rate of 50%. In terms of safety, 11 patients experienced Grade 1 CRS, and 1 patient experienced Grade 2 ICANS, all of whom have recovered

JW THERAP-B announced that the company has submitted Phase I study data of Ruijiaolun's injection for adult patients with active systemic lupus erythematosus to the National Medical Products Administration of China. As of July 2025, the study has enrolled 12 subjects and completed the infusion of Ruijiaolun injection, preliminarily completing the exploration of safety, efficacy, pharmacokinetics, and pharmacodynamics in low, medium, and high dose groups. All subjects were female, with a median age of 27 years and a median disease history of 9.5 years, all being moderate to severe active SLE patients. Preliminary results showed that among the 12 patients with assessable efficacy at 6 months, 100% met the SRI-4 criteria, 50% met the LLDAS criteria, and 100% were Drug-Free. Disease activity scale scores showed a downward trend, indicating significant efficacy. Safety results showed that 11 patients experienced CRS, all of which were Grade 1, and 1 patient experienced Grade 2 ICANS, which resolved after symptomatic treatment, with no DLT. The Phase I clinical study of Ruijiaolun for moderate to severe active SLE demonstrated good safety and significant efficacy

### Related Stocks

- [02126.HK - JW THERAP-B](https://longbridge.com/en/quote/02126.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 索羅斯逆市加碼微軟及 Nvidia 等科企 新買入黃金股 清倉 4 隻股份 | 索羅斯基金管理公司在 2022 年第四季度加大對微軟、英偉達和蘋果等大型科技股的投資，同時增持黃金股以對衝風險。基金還增持了 Atlassian、Salesforce 和 Uber 等軟體公司股票，但大幅減持了 Snowflake 和 Ci | [Link](https://longbridge.com/en/news/275990619.md) |
| 阿里及百度等擬被納入中國軍事企業清單 阿里斥毫無依據 ADR 仍較港股高水 | 阿里巴巴、百度等多家中國企業被列入美國政府的軍事企業清單，導致其美股價格下跌。阿里巴巴對此表示強烈反對，稱提議毫無依據，並將採取法律行動。被列入清單的企業還包括藥明康德和比亞迪等。根據新法，美國國防部未來將禁止與這些公司籤訂合同。該清單自  | [Link](https://longbridge.com/en/news/275920335.md) |
| 美國 1 月 CPI 來襲！標普 500、輝達、德國 DAX 指數、澳元/美元技術分析 | 美國勞工統計局將於 2 月 13 日發布 1 月消費者價格指數（CPI），預計服務價格漲幅放緩將導致通脹降温，但核心通脹率可能上升。1 月非農就業數據強勁，促使市場對美聯儲降息次數的預期減少。標普 500 指數在 2 月 12 日下跌 1. | [Link](https://longbridge.com/en/news/275974381.md) |
| 英偉達的股價能否逼近 400 美元？以下是收益可能標誌着大幅上漲開始的原因 | 英偉達的股票在今年一直停滯不前，但 Cantor Fitzgerald 的分析師 C.J. Muse 認為，2 月 25 日即將發佈的財報可能會成為轉折點。他預計關於英偉達 Blackwell AI 芯片的產量提升將傳來積極消息，並且對計算 | [Link](https://longbridge.com/en/news/276149614.md) |
| Coatue Management 減少了在 NVIDIA、特斯拉和 Oracle 的股份，並清空了在 Pinterest 的持股 | Coatue Management 對其股權進行了重大調整，具體情況在 SEC 文件中有所披露。該公司將其在英偉達的持股減少了 6.8%，降至 920 萬股；在特斯拉的持股減少了 5.1%，降至 160 萬股；在甲骨文的持股減少了 7.4% | [Link](https://longbridge.com/en/news/276178403.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.